{
    "clinical_study": {
        "@rank": "102657", 
        "arm_group": {
            "arm_group_label": "Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Vaccine\nFlubio (Influenza HA) vaccine\n2 doses for infants and children (6 months - 8 years old)\n1 doses for children (9-11 years old)\nThe vaccine will be given intramuscularly"
        }, 
        "brief_summary": {
            "textblock": "To Asses the Immunogenicity and Safety of Flubio (Influenza HA) Vaccine in Infants and\n      Children (Bridging Study)"
        }, 
        "brief_title": "Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Too see percentage of subjects with HI titer >= 1:40, 28 days after two doses in infants and\n      children (6 months-8 years old) and one dose in children 9-11 years old for each strain."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy\n\n          -  Parents have been informed properly regarding the study and signed the informed\n             consent form\n\n          -  Parents will commit themselves to comply with the instructions of the investigator\n             and the schedule of the trial\n\n        Exclusion Criteria:\n\n          -  Subjects concomitantly enrolled or scheduled to be enrolled in another trial\n\n          -  Evolving mild, moderate, or severe illness, especially infectious diseases or fever\n             (axillary temperature >=37oC)\n\n          -  Known history of allergy to egg and/or chicken protein or any other component of the\n             vaccines\n\n          -  Known history of uncontrolled coagulopathy or blood disorders contraindicating\n             intramuscular injection\n\n          -  Subject who has received a treatment likely to alter the immune response in the\n             previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term\n             corticotherapy (>2 weeks)).\n\n          -  Any abnormality or chronic disease justified by investigator that might interfere\n             assessment of the trial objectives.\n\n          -  Subjects has been immunized with influenza vaccine within 1 year\n\n          -  Subjects receives any vaccination within 1 months before and after immunization of\n             Flubio."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "11 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "405", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093260", 
            "org_study_id": "Influenza 0213"
        }, 
        "intervention": {
            "arm_group_label": "Vaccine", 
            "description": "Flubio (Influenza HA) Vaccine\nThe vaccine will be given intramuscularly.", 
            "intervention_name": "Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Flubio"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Flubio Vaccine (Influenza HA)", 
            "Infants", 
            "Children", 
            "Safety", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Bernie Endyarni, MD", 
                    "phone": "+628158024517"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Jatinegara Primary Health Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bernie Endyarni, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Primary School of SDN 01 Kampung Melayu"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II b Study of Immunogenicity and Safety of Flubio Vaccine in Infants and Children", 
        "overall_contact": {
            "last_name": "Bernie Endyarni, MD", 
            "phone": "+628158024517"
        }, 
        "overall_official": {
            "affiliation": "Department of Child Health School of Medicine, University of Indonesia", 
            "last_name": "Bernie Endyarni, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of subjects with anti HI titer >=1:40", 
            "measure": "To asses the immunogenicity of Flubio vaccine 28 days after 2 doses immunization in infants and children (6 months-8 years of age) and 1 dose immunization in children (9-11 years of age)", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage subjects with increasing antibody titer >=4 times", 
                "measure": "To describe the seroconversion after 2 doses of Flubio vaccine in infants and children (6 months-8 years old)", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Percentage of subjects with transition of seronegative to seropositive", 
                "measure": "To describe seroconversion after 1 dose of Flubio vaccine in children (9-11 years old)", 
                "safety_issue": "No", 
                "time_frame": "1 months"
            }, 
            {
                "description": "Local and Systemic Reaction following immunization", 
                "measure": "To asses the safety of Flubio vaccine", 
                "safety_issue": "Yes", 
                "time_frame": "1-2 months"
            }
        ], 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}